[{"orgOrder":0,"company":"MicuRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"MicuRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx \/ Undisclosed"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Ertapenem","moa":"Bacterial penicillin-binding protein","graph1":"Podiatry","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"NovaLead Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Esmolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaLead Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"VA Northern California Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ VA Northern California Health Care System","highestDevelopmentStatusID":"10","companyTruncated":"VA Office of Research and Development \/ VA Northern California Health Care System"},{"orgOrder":0,"company":"Dipexium Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Cytolex","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase III","graph3":"Dipexium Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dipexium Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dipexium Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dipexium Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Cytolex","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase III","graph3":"Dipexium Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dipexium Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dipexium Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Olympus Biotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Trafermin","moa":"Fibroblast growth factor receptor 2","graph1":"Podiatry","graph2":"Phase III","graph3":"Olympus Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Olympus Biotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olympus Biotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Olympus Biotech Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Trafermin","moa":"Fibroblast growth factor receptor 2","graph1":"Podiatry","graph2":"Phase III","graph3":"Olympus Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Olympus Biotech Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Olympus Biotech Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Engensis","moa":"HGF receptor","graph1":"Podiatry","graph2":"Phase III","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Podiatry","graph2":"Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Podiatry","graph2":"Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ON101","moa":"Immune","graph1":"Podiatry","graph2":"Phase III","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Anterogen Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Allo-Asc","moa":"Mesenchymal stem cell","graph1":"Podiatry","graph2":"Phase III","graph3":"Anterogen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterogen Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anterogen Co \/ Undisclosed"},{"orgOrder":0,"company":"Cali Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CPL-01","moa":"Na channel-alpha-subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Cali Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cali Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cali Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ITALY","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Podiatry","graph2":"Phase III","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Janssen-Cilag \/ Grunenthal"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Podiatry","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Adocia","sponsor":"Virchow Group","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"FRANCE","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Biochaperone Pdgf-Bb","moa":"PDGF","graph1":"Podiatry","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Virchow Group","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Virchow Group"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Granexin","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xequel Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xequel Bio \/ Undisclosed"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Medical University of South Carolina | Spartanburg Regional Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Granexin","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xequel Bio \/ Medical University of South Carolina | Spartanburg Regional Healthcare System","highestDevelopmentStatusID":"10","companyTruncated":"Xequel Bio \/ Medical University of South Carolina | Spartanburg Regional Healthcare System"},{"orgOrder":0,"company":"PainReform","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"PainReform","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PainReform \/ Lotus Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Lotus Clinical Research"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Osiris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CHAM","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Osiris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osiris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Osiris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Dehydrated Human Amnion Chorion Membrane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"Energenesis Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ENERGI-F703","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Energenesis Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Energenesis Biomedical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Energenesis Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Energenesis Biomedical","sponsor":"A2 Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ENERGI-F703","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Energenesis Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Energenesis Biomedical \/ A2 Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Energenesis Biomedical \/ A2 Healthcare"},{"orgOrder":0,"company":"European Egyptian Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"EGYPT","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Pedyphar","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"European Egyptian Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"European Egyptian Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"European Egyptian Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"European Egyptian Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"EGYPT","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Royal Jelly","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"European Egyptian Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"European Egyptian Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"European Egyptian Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Alira Health","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Skinte","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Alira Health","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Alira Health"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Professional Education and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Skinte","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Professional Education and Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Professional Education and Research Institute"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"SkinTE","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Undisclosed"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Amniox Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Amniox Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amniox Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amniox Medical \/ Undisclosed"},{"orgOrder":0,"company":"GWT-TUD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"GERMANY","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Urokinase","moa":"Urokinase-type plasminogen activator","graph1":"Podiatry","graph2":"Phase III","graph3":"GWT-TUD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GWT-TUD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GWT-TUD \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
